Navigation Links
Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial
Date:3/12/2008

eting and look forward to this pivotal assessment of HD-02 as a treatment for slowing Huntington's disease for which there currently is no approved treatment," stated Belinda Tsao Nivaggioli, CEO and Chairman of Avicena. "We are also pleased to further strengthen our on-going relationship with Dr. Steven Hersch, Dr. Diana Rosas, and Dr. Bernard Ravina. We look forward to working with the NCCAM, a Division of NIH, and the Orphan Products Division through their sponsorship of this trial."

"We are very enthusiastic about the study results of HD-02 to date and excited to be advancing it into a Phase III trial," stated lead investigator Dr. Steven Hersch. "This Phase III study will evaluate whether HD-02 can slow the progression of Huntington's disease, and pending positive results, may provide a much needed treatment option to Huntington's patients."

ABOUT HD-02

HD-02 is a novel and proprietary drug candidate for the treatment of Huntington's disease (HD). HD-02 has been granted orphan drug designation in the U.S. Results from a Phase II clinical trial of HD-02, led by Dr. Steven Hersch of Massachusetts General Hospital, were published in the January 24, 2006 issue of Neurology and showed that HD-02 suppressed a Huntington's disease marker. Some researchers have linked this oxidative marker as a measure of cellular injury. Earlier preclinical studies performed by Dr. Flint Beal of Cornell Medical Center and Dr. Robert Ferrante of Boston University, showed that HD-02 has significant neuroprotective effects, such as improved movement, reduced neuropathology, and prolonged survival.

ABOUT HUNTINGTON'S DISEASE

Huntington's disease is a progressive neurodegenerative disease caused by a defective gene that is often inherited from parent to child. This genetic defect causes a widespread deterioration of neurons in those parts of the brain that are responsible for controlling cognitive, emotional and motor functions. This progressive deteriora
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
2. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
3. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
4. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
5. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
6. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
11. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... Diego, California (PRWEB) January 22, 2015 ... Promotional Offer to their comprehensive portfolio of Eppendorf ... allows customers to purchase a Centrifuge 5424/5424 R and ... Bundle of either Eppendorf Research plus or Eppendorf Reference ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... 10:00 CET, AMSTERDAM, February 20 Amsterdam Molecular,Therapeutics (Euronext: AMT), ... full year 2007 results., Highlights - ... Cash & cash equivalents of EUR 51.3 million at June 30, ... AMT 011 - Positive results of Phase I/II in LPL ...
... new technologies launched onboard a U.S. Naval Academy satellite ... space. One technology is a sensor that can check ... "film" that can control heat. , These technologies were ... Md.; NASAs Ames Research Center, Moffett Field, Calif.; and ...
... a collaboration between researchers at the National Institute of ... of Kentucky potentially offers a low-cost way to mass ... sheets for a wide range of applications including flexible ... for field diagnostics. , In a paper posted this ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Reports Full Year Results 2007 2Amsterdam Molecular Therapeutics Reports Full Year Results 2007 3Amsterdam Molecular Therapeutics Reports Full Year Results 2007 4Amsterdam Molecular Therapeutics Reports Full Year Results 2007 5Amsterdam Molecular Therapeutics Reports Full Year Results 2007 6Amsterdam Molecular Therapeutics Reports Full Year Results 2007 7NASA MidSTAR-1 successful technologies may be revolutionary 2NASA MidSTAR-1 successful technologies may be revolutionary 3NASA MidSTAR-1 successful technologies may be revolutionary 4Directed self-ordering of organic molecules for electronic devices 2
(Date:1/22/2015)... Wis. , Jan. 15, 2015  BellBrook Labs, ... drug discovery, announced the launch of a TR-FRET ... the company,s Transcreener UDP Assay, a high throughput ... The new assay will allow for sensitive detection ...
(Date:1/22/2015)... 22, 2015 , Europe,s ... The European Patent Office to present a video retrospective of ... to be featured: Christofer Toumazou and Sophie Wilson ... and winners of the Award   Starting on 22 ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES debut of ... Robbins will be at the NXT-ID booth January 6th ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... peculiarities with the DNA of just about every other plant ... as transposons, or "jumping genes," which have the ability to ... cell. An astounding 50% of human DNA ... former transposons that were active thousands to millions of years ...
... (Sept. 6, 2011) The American Physiological ... and the ENaC/Degenerin Family of Ion Channels, being held ... Grove, Calif. This scientific conference explores the connection ... growing global health concern. The five-day program ...
... surgeons are working together to improve the treatment of ... bone plates in the skull to fuse too soon. ... remove portions of the fused skull bones, and in ... -- requiring additional surgeries. Researchers in the Atlanta-based ...
Cached Biology News:A 'jumping gene's' preferred targets may influence genome evolution 2A 'jumping gene's' preferred targets may influence genome evolution 3Highlights of upcoming conference on aldosterone & the ENaC/Degenerin family of ion channels 2Developing technologies to improve the treatment of craniosynostosis in children 2Developing technologies to improve the treatment of craniosynostosis in children 3Developing technologies to improve the treatment of craniosynostosis in children 4
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
Request Info...
Biology Products: